Edoxaban p-toluenesulfonate monohydrate is primarily used as an anticoagulant in the prevention and treatment of thromboembolic disorders. It is specifically prescribed to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. Additionally, it is utilized for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following initial parenteral anticoagulation and to prevent recurrence of these conditions. It is also indicated for the prevention of venous thromboembolism (VTE) in patients undergoing elective hip or knee replacement surgery. Its mechanism involves direct inhibition of Factor Xa, which plays a key role in the blood coagulation cascade, thereby preventing the formation of blood clots. It is often chosen for its oral bioavailability and predictable pharmacokinetics, making it a convenient option for long-term anticoagulation therapy.